Table 2.
Risk for development of composite of ≥40% eGFR decline or ESKD events by baseline albuminuria status
| ≥40% eGFR Decline by eGFR-Creatinine, eGFR–Cystatin C, or ESKD Events | 1.5 mg Dulaglutide (N=192) | 0.75 mg Dulaglutide (N=190) | Insulin Glargine (N=194) | |||
| n/N (%) | HR (95% CI) | n/N (%) | HR (95% CI) | n/N (%) | ||
| Overall population | ||||||
| eGFR-creatinine | 10/192 (5) | 0.45 (0.20 to 0.97)a | 16/190 (8) | 0.79 (0.41 to 1.51) | 21/194 (11) | |
| eGFR–cystatin C | 11/192 (6) | 0.49 (0.23 to 1.04) | 15/190 (8) | 0.73 (0.38 to 1.42) | 21/194 (11) | |
| Normoalbuminuria (UACR, <30 mg/g) | ||||||
| eGFR-creatinine | 2/34 (6) | NA | 0/44 | NA | 0/48 | |
| eGFR–cystatin C | 3/34 (9) | NA | 0/44 | NA | 1/48 (2) | |
| Microalbuminuria (UACR, 30–300 mg/g) | ||||||
| eGFR-creatinine | 2/74 (3) | 1.59 (0.14 to 17.48) | 2/61 (3) | 1.96 (0.18 to 21.66) | 1/56 (2) | |
| eGFR–cystatin C | 2/74 (3) | 1.59 (0.14 to 17.48) | 2/61 (3) | 1.96 (0.18 to 21.66) | 1/56 (2) | |
| Macroalbuminuria (UACR, >300 mg/g) | ||||||
| eGFR-creatinine | 6/84 (7) | 0.25 (0.10 to 0.68)a | 14/84 (17) | 0.72 (0.36 to 1.43) | 20/90 (22) | |
| eGFR–cystatin C | 6/84 (7) | 0.26 (0.10 to 0.71)a | 13/84 (16) | 0.70 (0.34 to 1.41) | 19/90 (21) | |
eGFR-creatinine, eGFR determined using the Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation; eGFR–cystatin C, eGFR determined using the Chronic Kidney Disease Epidemiology Collaboration Cystatin C Equation; n, number of participants with events; N, total number of participants; HR, hazard ratio relative to insulin glargine; UACR, urinary albumin-creatinine ratio; NA, not applicable.
a
Statistically significant versus insulin glargine (P<0.05).